The non-selective CDK9 inhibitor CDKI-73 proved anti-proliferative and pro-apoptotic capacity in chronic lymphoblastic leukemia (CLL) [63], diffuse large B-cell lymphoma [64], ALL and AML [65] cells, as well as in animal models. The gene discussed is CDK9; the disease is diffuse large B-cell lymphoma.